Section Arrow
MBRX.NASDAQ
- Moleculin Biotech Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/10/21 00:43 EDT
Regular Hours
Last
 6.19
+0.89 (+16.79%)
Day High 
6.4025 
Prev. Close
5.3 
1-M High
14.66 
Volume 
131.77K 
Bid
5.52
Ask
6.3
Day Low
5.24 
Open
5.74 
1-M Low
4.42 
Market Cap 
5.40M 
Currency 美元 
P/E 0.02 
%Yield -- 
10-SMA 7.85 
20-SMA 9.25 
50-SMA 11.49 
52-W High 315 
52-W Low 3.228 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
14.59/-1.17
Enterprise Value
5.62M
Balance Sheet
Book Value Per Share
0.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
EYPTEyePoint Inc.0.4052-0.0348-7.91%-- 
RXRXRecursion Pharmaceuticals3.66+0.05+1.39%-- 
MRNAModerna242.08+15.19+6.69%-- 
IBRXImmunityBio8.77+0.35+4.16%-- 
SLNSilence Therapeutics Plc19.61+0.03+0.15%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.